Worried your AI pilots stall at deployment? In the past 14 days major vendors pushed capabilities that make operationalization the real battleground — here’s what to know for your roadmap. Big labs shipped on-device multimodal tools (xAI’s Grok-2-mini, API live 2025-12-23; Apple’s MLX quantization updates 2025-12-27), agent frameworks added observability and policy (Microsoft Azure AI Agents preview 2025-12-20; LangGraph RC 1.0 on 2025-12-30), and infra vendors published runbooks (HashiCorp refs 2025-12-19; Datadog LLM Observability GA 2025-12-27). Quantum roadmaps emphasize logical qubits (IBM target: 100+ logical qubits by 2029; Quantinuum reports logical error 50% on 2025-12-22; Beam showed >70% in-vivo editing on 2025-12-19; Nasdaq piloted LLM triage reducing false positives 20–30% on 2025-12-21). Bottom line: focus less on raw model quality and more on SDK/hardware integration, SRE/DevOps, observability, and governance to actually deploy value.

In the last ~14 days the in vivo gene‐editing field accelerated: Azalea Therapeutics (co‐founded by Jennifer Doudna) raised US$82M Series A led by Third Rock to advance a single‐dose dual‐vector permanent genome‐editing approach targeting an in vivo CAR‐T for B‐cell malignancies, aiming for the clinic in 12–18 months; Stylus Medicine secured $85M from investors including J&J and Eli Lilly to build next‐generation in vivo genetic medicines; and Vertex ended its Verve collaboration, reclaiming a liver program while deprioritizing certain delivery platforms. These developments shift investor appetite toward clinically directed, scalable delivery solutions, raise regulatory and safety scrutiny around vectors and durability, and create near‐term catalysts to watch: IND submissions/first dosing, preclinical safety data on novel delivery vectors, and regulatory guideline updates.